Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAWN: PCSK9 Inhibitor + Statin in ACS After PCI
NCT05457582Active, not recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial of alirocumab and tafolecimab in acute coronary syndrome (ACS) and hyperlipidemia (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Cardiovascular events at 12 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
alirocumabtafolecimab
03
Conditions
acute coronary syndrome (ACS)hyperlipidemia
Beyond the preview
Go deeper on NCT05457582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457582.